Treatment for Uncomplicated Genital Chlamydia
For uncomplicated genital Chlamydia trachomatis infection in non-pregnant adults, treat with either azithromycin 1 g orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days—both regimens are equally effective with 97-98% cure rates. 1
First-Line Treatment Options
The two recommended regimens are:
- Azithromycin 1 g orally, single dose
- Doxycycline 100 mg orally twice daily for 7 days
Both options demonstrate equivalent microbiological cure rates based on meta-analysis of 12 randomized trials 1. The choice between them depends on practical considerations rather than efficacy differences.
When to Choose Azithromycin
Select azithromycin for patients with:
- Questionable compliance or adherence concerns
- Erratic healthcare-seeking behavior
- Unpredictable follow-up
- Need for directly observed therapy
The single-dose regimen ensures complete treatment administration and may be more cost-effective in populations where treatment completion is uncertain 1, 2.
When to Choose Doxycycline
Doxycycline is preferable when:
- Cost is a primary concern (significantly less expensive than azithromycin)
- Patient can reliably complete a 7-day course
- Follow-up is assured
Doxycycline has a longer track record of extensive use and carries no higher risk for adverse events compared to azithromycin 1.
Alternative Regimens
If first-line options cannot be used, alternatives include 1:
- Erythromycin base 500 mg orally four times daily for 7 days
- Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
- Ofloxacin 300 mg orally twice daily for 7 days
- Levofloxacin 500 mg orally once daily for 7 days
Important caveat: Erythromycin is less efficacious than azithromycin or doxycycline, primarily due to gastrointestinal side effects that reduce compliance 1. The quinolones (ofloxacin, levofloxacin) offer no dosing advantage and are more expensive 1, 2.
Critical Management Points
Medication Dispensing
Dispense medications on-site whenever possible and directly observe the first dose to maximize compliance 1.
Sexual Abstinence
Instruct patients to abstain from sexual intercourse for 7 days after single-dose therapy or until completion of the 7-day regimen 1. This minimizes transmission risk.
Partner Treatment
All sexual partners from the preceding 60 days must be evaluated and treated for both chlamydia and gonorrhea (due to frequent coinfection), even if asymptomatic 1.
Follow-Up Considerations
Test of Cure
Not recommended for non-pregnant patients treated with recommended regimens, unless 1:
- Therapeutic compliance is questionable
- Symptoms persist
- Reinfection is suspected
Testing performed less than 3 weeks after treatment completion may yield false results—false negatives from low organism numbers or false positives from dead organisms 1.
Repeat Testing
Retest all women approximately 3 months after treatment regardless of whether partners were treated 1. This addresses the high prevalence of reinfection (often from untreated partners or new infected partners), which confers elevated risk for pelvic inflammatory disease and complications compared to initial infection 1.
Special Populations
Pregnant Women
Contraindications: Doxycycline, ofloxacin, and levofloxacin are absolutely contraindicated in pregnancy 1.
Recommended for pregnancy:
- Azithromycin 1 g orally, single dose (safe and effective)
- Amoxicillin 500 mg orally three times daily for 7 days
Pregnant women require repeat testing (preferably by NAAT) 3 weeks after treatment completion to ensure therapeutic cure, given potential maternal and neonatal sequelae 1.
HIV-Infected Patients
Treat with the same regimens as HIV-negative patients—no modification needed 1, 2.
Common Pitfalls to Avoid
Don't test too early: Avoid testing within 3 weeks of treatment completion to prevent false results 1
Don't forget coinfection: Always consider concurrent gonorrhea treatment, as coinfection is common 1, 3
Don't neglect partner notification: Failure to treat partners is the primary cause of reinfection 1
Don't skip retesting in women: The 3-month retest is crucial for identifying reinfections that increase PID risk 1
Don't use quinolones in pregnancy or adolescents: Age and pregnancy restrictions apply to fluoroquinolones 3, 4